首页> 美国卫生研究院文献>Public Health Ethics >Lifestyle Vaccines and Public Health: Exploring Policy Options for a Vaccine to Stop Smoking
【2h】

Lifestyle Vaccines and Public Health: Exploring Policy Options for a Vaccine to Stop Smoking

机译:生活方式疫苗和公共卫生:探索政策来停止吸烟

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Experimental vaccines are being developed for the treatment of ‘unhealthy lifestyles’ and associated chronic illnesses. Policymakers and other stakeholders will have to deal with the ethical issues that this innovation path raises: are there morally justified reasons to integrate these innovative biotechnologies in future health policies? Should public money be invested in further research? Focusing on the case of an experimental nicotine vaccine, this article explores the ethical aspects of ‘lifestyle vaccines’ for public health. Based on findings from a qualitative study into a vaccine for smoking cessation, the article articulates possible value conflicts related to nicotine vaccination as an intervention in tobacco control. The ‘vaccinization’ of lifestyle disease piggybacks on the achievements of classic vaccines. Contrary to expectations of simplicity and success, quitting smoking with a vaccine requires a complex supportive network. Social justice and public trust may become important ethical challenges when deciding whether to use further public funds for research or whether to implement these innovative vaccines in the future.
机译:正在开发实验性疫苗来治疗“不良生活方式”和相关的慢性病。决策者和其他利益相关者将不得不应对这种创新之路引发的伦理问题:在道德上有正当理由将这些创新生物技术整合到未来的卫生政策中吗?是否应该将公共资金用于进一步研究?本文着重于实验性尼古丁疫苗的案例,探讨了用于公共卫生的“生活方式疫苗”的道德方面。基于对戒烟疫苗的定性研究发现,本文阐明了与尼古丁疫苗接种相关的可能的价值冲突,以此作为控制烟草的干预措施。生活方式疾病的“疫苗接种”取决于经典疫苗的成就。与简单性和成功的期望相反,用疫苗戒烟需要复杂的支持网络。在决定是否使用更多的公共资金进行研究或将来是否实施这些创新疫苗时,社会正义和公众信任可能成为重要的伦理挑战。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号